Targeted protein degradation (TPD) is an emerging modality for research and therapeutics.
Most TPD approaches harness cellular ubiquitin-dependent proteolytic pathways …

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce
degradation of a target by simultaneously binding to a ubiquitin ligase. More generally …

Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer
therapies, often arising from target engagement in nonmalignant tissues. This obstacle can …

Kinetics of the PROTAC‐induced protein degradation were modelled using the equilibrium
approximation, accounting for the protein recovery rate with a time lag. The simulated kinetic …

Bruton's tyrosine kinase (BTK) is an attractive target in inflammatory and autoimmune
diseases. However, the effectiveness of BTK inhibitors is limited by side effects and drug …

Proteolysis-targeting chimeras (PROTACs) that engage two biological targets at once are a
promising technology in degrading clinically relevant protein targets. Since factors that …

Biophysical research plays a crucial role in drug discovery, but many druglike molecules are
poorly soluble and prone to aggregation, making their analysis challenging and susceptible …

The modulation of protein-protein interactions with small molecules is one of the most
rapidly developing areas in drug discovery. In this review, we discuss advances over the …

Small molecule degraders of disease-driving proteins offer a clinically proven modality with
enhanced therapeutic efficacy and the potential to tackle previously undrugged targets …

Introduction Escalating costs and inherent uncertainties associated with drug discovery
invite initiatives to improve its efficiency and de-risk campaigns for inventing better …